Genetic screening in hereditary medullary thyroid carcinoma

Acta Chirurgica Austriaca

Volumn 29, Issue 1, 1997, Pages 5-8

  Eng, Charis ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Genetic testing; Inherited cancer syndrome; MEN 2; MTC; RET

Indexed keywords

PROTEIN TYROSINE KINASE; RESTRICTION ENDONUCLEASE;

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CODON; DNA DETERMINATION; ENDOCRINE TUMOR; EXON; FAMILIAL CANCER; GENE MUTATION; GENETIC SCREENING; HUMAN; HYPERPARATHYROIDISM; PHEOCHROMOCYTOMA; POLYMERASE CHAIN REACTION; PROPHYLAXIS; PROTO ONCOGENE; THYROID MEDULLARY CARCINOMA;

EID: 0030915407     PISSN: 0001544X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02620265     Document Type: Article

References (50)

1. Ponder BAJ: Medullary thyroid cancer: screening the family of the apparently sporadic case. In Muller HJ WW (ed): Familial Cancer. Basel: Kargel, 1985, pp 112-114.
2. Gagel RF, Tashjian AH, Cummings T, Papathanasopoulos N, Kaplan MM, DeLellis RA, Wolfe HJ, Reichlin S: The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. N Engl J Med 1988;318:478-484.
3. Schimke RN: Genetic aspects of multiple endocrine neoplasia. Ann Rev Med 1984;35:25-31.
4. Schimke RN, Hartmann WH, Prout TW, Rimoin DL: Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas. N Engl J Med 1968;279:1-7.
5. Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, Wells SA: Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986;73:278-281.
6. Takahashi M, Ritz J, Cooper GM: Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42:581-588.
7. Takahashi M, Cooper GM: RET transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 1987;3:1378-1385.
8. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H: Cloning and expression of the ret proto-oncogene encoding a receptor tyrosine kinase with two potential transmembrane domains. Oncogene 1988;3:571-578.
9. Durbec P, Marcos-Gutierrez CV, Kilkenny C, Grigoriou M, Wartiowaara K, Suvanto P, Smith D, Ponder B, Costantini F, Saarma M, Sariola H, Pachnis V: Glial cell linederived neurotrophic factor signalling through the Ret receptor tyrosine kinase. Nature 1996;381:789-793.
10. Bongarzone I, Monzini N, Borrello MG, Carcano C, Ferraresi G, Arighi E, Mondellini P, Della Porta G, Pierotti MA: Molecular characterisation of a thyroid tumorspecific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI of cyclic AMP-dependent protein kinase A. Mol Cell Biol 1993;13:358-366.
11. Kwok JBJ, Gardner E, Warner JP, Ponder BAJ, Mulligan LM: Structural analysis of the human ret proto-oncogene by exon trapping. Oncogene 1993;8:2572-2582.
12. Lorenzo MJ, Eng C, Mulligan LM, Stonehouse TJ, Healey CS, Ponder BAJ, Smith DP: Multiple mRNA isoforms of the human RET proto-oncogene generated by alternate splicing. Oncogene 1995;10:1377-1383.
13. Myers SM, Eng C, Ponder BAJ, Mulligan LM: Characterization of RET protooncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 1995;11:2039-2045.
14. Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T: Expression of the ret protooncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 1994;172:255-260.
15. Santoro M, Rosato R, Grieco M, Berlingieri MT, Luca-Colucci D'Amato G, de Franciscis V, Fusco A: The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 1990;5:1595-1598.
16. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856.
17. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ: Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-460.
18. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann HPH, Thibodeau SN, Ponder BAJ: Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet 1994;6:70-74.
19. Mulligan LM, Eng C, Healey CS, Ponder MA, Feldman GL, Li P, Jackson CE, Ponder BAJ: A de novo mutation of the RET proto-oncogene in a patient with MEN 2A. Hum Mol Genet 1994;3:1007-1008.
20. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJM, Gagel RF, Takai S-I, Noll WW, Fink M, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder BAJ, Eng C: Genotype-phenotype correlation in MEN 2: Report of the International RET Mutation Consortium. J Intern Med 1995;238:343-346.
21. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP: Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 1995;267:381-383.
22. Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, Modigliani E, Lenoir GM, GETC: RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994;3:1939-1943.
23. Frank-Raue K, Höppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendl J, Deckart HF, Ritter MM, Hampel R, Klempa J, Scholz GH, Raue F, Group GMTCS: Mutations of the RET proto-oncogene in German MEN families: relation between genotype and phenotype. J Clin Endocrinol Metab 1996;81:1780-1783.
24. Hofstra R, Stelwagen T, Stulp R, Timmer T, Nijveen H, Sijmons R, Scheffer H, Buys C: RET mutations in MEN 2 associated diseases. Am J Hum Genet 1994;55 (suppl A60).
25. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BAJ: A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509-513.
26. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, Tourniaire J, Lenoir GM, Romeo G: RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995;10:2415-2419.
27. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA, Goodfellow PJ, Donis-Keller H: Single missense mutation in the tyrosine kinase catalytic domain of the RETprotooncogene is associated with multiple endocrine neoplasia type 28. Proc Natl Acad Sci (USA) 1994;91:1579-1583.
28. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GFW, Jackson CE, Tunnacliffe A, Ponder BAJ: Point mutation within the tyrosine kinase domain of the RETproto-oncogene in multiple endocrine neoplasia type 28 and related sporadic tumours. Hum Mol Genet 1994;3:237-241.
29. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y. Pasini B, Höppener JWM, Ploos van Amstel HK, Romeo G, Lips CJM, Buys CHCM: A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 28 and sporadic medullary thyroid carcinoma. Nature 1994;367:375-376.
30. Rossel M, Schuffenecker I, Schlumberger M, Bonnardel C, Modigliani E, Gardel P, Navarro J, Luo Y, Romeo G, Lenoir G, Billaud M: Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families. Hum Genet 1995;95:403-406.
31. Songyang Z, Carraway III KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C, Lorenzo MJ, Ponder BAJ, Mayer BJ, Cantley LC: Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 1995;373:536-539.
32. Toogood AA, Eng C, Smith DP, Ponder BAJ, Shalet SM: No mutation at codon 918 of the RET gene in a family with multiple endocrine neoplasia type 28. Clin Endocrinol 1995;43:759-762.
33. McMahon R, Mulligan LM, Healey CS, Payne SJ, Ponder M, Ferguson-Smith MA, Barton DE, Ponder BAJ: Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families, Hum Mol Genet 1994;3:643-646.
34. Lips CJM, Landsvaler RM, Hoppener JWM, Geerdink RA, Blijham G. Jansen-Schillhorn van Veen JM, van Gils APG, de Wit MJ, Zewald RA, Berends MJH, Beemer FA, Brouwers-Smalbraak J, Jansen RPM, Ploos van Amstel HK, JMV vV, Vroom TM: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:828-835.
35. Marsh DJ, Robinson BG, Andrew S, Richardson A-L, Pojer R, Schnitzler M, Mulligan LM, Hyland VJ: A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families. Genomics 1994;23:477-479.
36. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson A-L, Delbridge L, Eng C, Robinson BG: Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 1996;44:249-257.
37. Wells SA, Chi DD, Toshima D, Dehner LP, Coffin CM, Darton B, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, Norton JA, Donis-Keller H: Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;200:237-250.
38. Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin E, Novell DF, Diamond T, Delbridge L, Clifton-Bligh P, Robinson BG: The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin Endocrinol 1996;44:213-220.
39. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HPH, Pfragner R, Behmel A, Lorenzo MJ, Stonehouse TJ, Ponder MA, Ponder BAJ: Mutation in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Genes Chrom Cancer 1995;12:209-212.
40. Blaugrund JE, Johns MM, Eby YJ, Ball DW, Baylin SB, Hruban RH, Sidransky D: RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 1994;3:1895-1897.
41. Zedenius J, Wallin G, Hamberger B, Nordenskjöld M, Weber G, Larsson C: Somatic und MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s. Hum Mol Genet 1994;3:1259-1262.
42. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G: Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1995;80:3088-3090.
43. Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christensen G, Colomer A, Roth J, Heitz PU: Analysis of RET proto-oncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer 1995;76:479-489.
44. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F: Somatic mutations of the RET proto-oncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996;81:1619-1622.
45. Don S, Chi D, Carlson KM, Moley JA, Wells SAJ, Donis-Keller H: RET proto-oncogene mutations associated with sporadic cases of medullary thyroid carcinoma. Fifth International Workshop Mult Endo Neopl 1994, 73 (abstr).
46. Marsh DJ, Andrew SD, Learoyd DL, Pojer R, Eng C, Robinson BG: Deletioninsertion mutation encompassing RET codon 634 is associated with medullary thyroid carcinoma. Hum Mutat 1996 (in press).
47. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HPH, Ponder MA, Ponder BAJ: Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 1995;43:123-127.
48. Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, Richardson A-L, Houghton C, Mulligan LM, Ponder BAJ, Robinson BG: Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 1996;56:1241-1243.
49. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BAJ: Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 1996;56:2167-2170.
50. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Ploos van Amstel HK, Lips CJM, Nishisho I, Takai S-I, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA 1996;276:1575-1579.